Navigation Links
Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
Date:3/17/2008

d greatly to our progress, and we wish them well in their future endeavors," continued Dr. Love.

Conference Call Information

Nuvelo will hold a conference call today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss this announcement. To participate in the conference call, please dial 866-854-8095 for domestic callers and 706-634-8567 for international callers and reference conference passcode, 39369496. A telephone replay of the conference call will be available through March 20, 2008. To access the replay, please dial 800-642-1687 for domestic callers and 706-645-9291 for international callers and reference conference passcode, 39369496.

In addition, this call is being webcast by Thomson/CCBN and can be accessed at Nuvelo's website at http://www.nuvelo.com. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to continue its research programs in leukemia and lym
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
2. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
3. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
4. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
5. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
6. Synbiotics Corporation Announces Human Submission for FluDetect(R)
7. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
8. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
9. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
10. Inclinix Announces New Patent for Expert System Platform
11. Genzyme Announces Presentation of New Positive Data on Carticel(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...ate TAXUS(R) Element(TM) Platinum Chromium ...t. 8 /- Boston Scientific,C...as completed enrollment in,the PERSEUS trial, desi...XUS(R) Element(TM) paclitaxel-eluting coronary ste...ly 1,500 patients at 100 U.S. and,international ce...
(Date:10/7/2008).../ -- Prometheus Laboratories Inc., a,specialty pha... its,development of PROMETHEUS(R) IBS Diagnostic, ...syndrome (IBS). The findings suggest measurable,di...rs in blood samples,between IBS and non-IBS patien...ed with a proprietary algorithm, led to the develo...
(Date:10/7/2008)...ted at the Osteoarthritis Research Society,Interna...ct. 7 /- Ferring Pharmaceuticals Inc....f Osteoarthritis of the,Knee, showing that EUFLEXX...ian high molecular weight form of intra-articular ...cular saline (IA-saline) for the relief,of pain in...
(Date:10/7/2008)..., VYVANSE taken once-daily significantly,improved ...A, Oct. 7 /- Shire plc (LSE...rmaceutical company, today,announced that a study ...,Clinical Psychiatry found once-daily VYVANSE sign... Disorder (ADHD) symptoms in adults within,the fir...
Breaking Medicine Technology:Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6DNA Coding May Make Bowel Prone to Cancer 21606 1DNA Coding May Make Bowel Prone to Cancer 21606 2Vitamin D 3A New way to treat heart failure 3F 3611 1Vitamin D 3A New way to treat heart failure 3F 3611 2Vitamin D 3A New way to treat heart failure 3F 3611 3Lupin Launches Ramipril Capsules 21601 1Lupin Launches Ramipril Capsules 21601 2Lupin Launches Ramipril Capsules 21601 3Zimpfer Named Executive Vice President General Counsel of Conseco 21597 1
...d in Cancer Research, TARRYTOWN, N.Y., June 15, 20...oday announced the results of scientific studies t...ffective in treating,multiple types of human tumor...h MPC-6827 exerts its effects, and (3) show that,M... to be involved,in cancer drug resistance. The stu...
...ing Influenza Conference, HIGH WYCOMBE, England, J...d pre-clinical data showing how a new flu vaccine ...f influenza, including,pandemic and annual, was pr... the Control of Influenza VI (Options) Conference,...hich will be published in the,European Journal of ...
Other Medicine Technology:New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 2New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 3New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 4
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...by Salim Yusuf and Koon Teo at the University of H...e increases the risk of heart attack.// The stud...at Tobacco use in all forms, whether smoked or che...es the risk of heart attack. The study was conduc...
...y for Punjab is bittersweet. While Punjab has don... managed to retain the fertility// level at two ch... with the soaring obesity rates. Nearly 38% women... revealed. The survey, conducted by CRRID in Pun...
... Mahim beach to drink sweet seawater for the secon...ople against drinking// the polluted water. Scien... due to the natural phenomenon of dilution. "Dilu...ved all along the western coast of India during th...
...ncer survivors are at an increased risk of develop... Christopher Recklitis and colleagues// at the Dan...g 226 patients aged 28. All patients were adult su...ents were interviewed at an average of 18 years af...
Other Medicine News:Health News:Maharashtra warns against Mahim's 'miracle' water 2
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology.
Lorgnette pinhole occluder
Long handle occluder - White
Double Ended Occluders
Medicine Products: